Companies / SNT

SYNTARA LIMITED

ASX:SNTPharmaceuticals, Biotechnology & Life Sciences
1.96B shares on issueASX (delayed) · as of 28 July 2026$0.022price · delayed$43.2Mmarket cap · indicative
C
Dilution grade

Share count grew 64% in 24 months; runway 2–4 quarters; 3 cash raises in 24 months

Cash runway3.3 quarters of funding
Share-count growth (24m)64.4%
Raise cadence (24m)3 cash raises
Options & rights overhang3.8% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

SYNTARA LIMITED's ordinary share count grew 64.4% between April 2024 and July 2026, to 1.96B shares. The company raised capital three times in that 24-month window for total disclosed proceeds of A$32.7M, most recently via a Placement and Share Purchase Plan that raised A$8.8M in May 2026. Options and rights on issue could convert into 75M new shares, equal to 3.8% of the current share count, with the nearest expiry in December 2027 and 0% in the money. At the June 2026 quarter SYNTARA reported A$12.4M in cash, equal to about 3.3 quarters of cover. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
3.8%
Max option dilution
0.0%
ITM option dilution
2
Raises · last 12 months
3.3 qtrs
Cash cover · 2–4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 1.96B per ASX (delayed) (28 July 2026).
1.50B1.67B1.84BDec 24Sept 25July 26Cash raise · 14 May 2026Cash raise · 24 Apr 2026Cash raise · 9 Dec 2024

Cash runway

3.3 qtrs
Two to four quarters of funding at the recent spend rate.
$12.4M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
2 July 20262A · quoted issueSNT : ORDINARY FULLY PAID1.96BAppendix 2A
2 July 20263G · unquotedSNT : ORDINARY FULLY PAID1.96BAppendix 3G
24 June 20262A · quoted issueSNT : ORDINARY FULLY PAID1.96BAppendix 2A
10 June 20262A · quoted issueSNT : ORDINARY FULLY PAID1.91BAppendix 2A
6 May 20262A · quoted issueSNT : ORDINARY FULLY PAID1.88BAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

3 cash raises in the last 24 months · 2 in the last 12 months

$8.8M
Placement and Share Purchase Plan
14 May 2026 COMPLETE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

3.8%
Total overhang · of current shares
0.0%
In the money · at current price
75.2M
Potential new shares
Dec 2027
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
24 Nov 2025Dr Kathleen MettersOther—3.0M—3Y notice
24 Nov 2025Gary Jonathan PhillipsOther—5.7M—3Y notice
20 Feb 2025Waradana Malitha Hashan De SilvaBuy9.8M3.0M$585k3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

28 July 2026Investor Update Webinar Presentation
26 July 2026Investor Update Webinar
26 July 2026Investor Presentation
26 July 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
20 July 2026AZALOX MDS study advances to final Phase 1b cohort
6 July 2026SNT-4728 Webinar Presentation
5 July 2026$PEncouraging SNT-4728 Phase 2 iRBD results
2 July 2026$PTrading Halt
2 July 2026Notification regarding unquoted securities - SNT
2 July 2026Application for quotation of securities - SNT
2 July 2026Proposed issue of securities to the CEO
1 July 2026SNT-9465 scarring trial exceeds 50% enrolment
29 June 2026Change in substantial holding
24 June 2026Section 708A(5)(e) notice
24 June 2026Application for quotation of securities - SNT
23 June 2026Results of Meeting
10 June 2026Application for quotation of securities - SNT
10 June 2026$PResults of Share Purchase Plan
1 June 2026SNT-4728 webinar presentation
28 May 2026SNT-4728 pre-readout informational webinar

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.